Anti-PRR7 monoclonal antibody

Anti-PRR7 antibody for FACS & in-vivo assay

Target products collectionGo to PRR7/PRR7 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1408-Ab-1/ GM-Tg-hg-MP1408-Ab-2Anti-Human PRR7 monoclonal antibodyHuman
GM-Tg-rg-MP1408-Ab-1/ GM-Tg-rg-MP1408-Ab-2Anti-Rat PRR7 monoclonal antibodyRat
GM-Tg-mg-MP1408-Ab-1/ GM-Tg-mg-MP1408-Ab-2Anti-Mouse PRR7 monoclonal antibodyMouse
GM-Tg-cynog-MP1408-Ab-1/ GM-Tg-cynog-MP1408-Ab-2Anti-Cynomolgus/ Rhesus macaque PRR7 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1408-Ab-1/ GM-Tg-felg-MP1408-Ab-2Anti-Feline PRR7 monoclonal antibodyFeline
GM-Tg-cang-MP1408-Ab-1/ GM-Tg-cang-MP1408-Ab-2Anti-Canine PRR7 monoclonal antibodyCanine
GM-Tg-bovg-MP1408-Ab-1/ GM-Tg-bovg-MP1408-Ab-2Anti-Bovine PRR7 monoclonal antibodyBovine
GM-Tg-equg-MP1408-Ab-1/ GM-Tg-equg-MP1408-Ab-2Anti-Equine PRR7 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1408-Ab-1/ GM-Tg-hg-MP1408-Ab-2; GM-Tg-rg-MP1408-Ab-1/ GM-Tg-rg-MP1408-Ab-2;
GM-Tg-mg-MP1408-Ab-1/ GM-Tg-mg-MP1408-Ab-2; GM-Tg-cynog-MP1408-Ab-1/ GM-Tg-cynog-MP1408-Ab-2;
GM-Tg-felg-MP1408-Ab-1/ GM-Tg-felg-MP1408-Ab-2; GM-Tg-cang-MP1408-Ab-1/ GM-Tg-cang-MP1408-Ab-2;
GM-Tg-bovg-MP1408-Ab-1/ GM-Tg-bovg-MP1408-Ab-2; GM-Tg-equg-MP1408-Ab-1/ GM-Tg-equg-MP1408-Ab-2
Products NameAnti-PRR7 monoclonal antibody
Formatmab
Target NamePRR7
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-PRR7 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species PRR7 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1408
    Target NamePRR7
    Gene ID80758,432763,498704,700123,611253,101087129,538641,100146129
    Gene Symbol and SynonymsPRR7,XM_484263
    Uniprot AccessionQ8TB68,P0C6T3
    Uniprot Entry NamePRR7_HUMAN,PRR7_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000131188
    Target ClassificationN/A

    The target: PRR7, gene name: PRR7, also named as . Enables long-chain fatty acid binding activity; protein tyrosine kinase binding activity; and ubiquitin-like protein ligase binding activity. Involved in negative regulation of protein ubiquitination; positive regulation of apoptotic process; and positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway. Located in several cellular components, including cytosol; nucleoplasm; and perinuclear region of cytoplasm. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.